Monitor upcoming regulatory filings for NYMOZARFEX; CEO share purchases may signal confidence, but absence of approval timelines limits near-term catalysts.
Price Chart
Executive Summary
Nymox Pharmaceutical announced board changes, including the retirement of Patrick Doody and the passing of Co-Chairman James G. Robinson. CEO Paul Averback purchased 50,000 shares, adding to a prior purchase of over 100,000 shares. The company noted progress on regulatory dossiers for its BPH treatment NYMOZARFEX, though no approvals have been granted yet.
Key Facts
- Patrick Doody retired from the Board of Directors.
- Co-Chairman James G. Robinson passed away; the company honored his long-term contributions.
- CEO Dr. Paul Averback purchased 50,000 shares in the open market, following a prior purchase of 102,844 shares in October 2025.
- The company reported that dossiers for its prostate treatments have been significantly updated, but no major regulatory approvals have been achieved yet.
- Nymox is advancing applications for NYMOZARFEX (Fexapotide), an in-office treatment for BPH with favorable clinical trial results to date.
Financial Impact
No direct financial impact disclosed; insider buying suggests confidence but no material change in capital structure or revenue.
Risk Factors
- Regulatory approval for NYMOZARFEX remains uncertain and delayed.
- Loss of key leadership figure James G. Robinson may impact strategic continuity.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001640334-26-000562 |
| Document: nymox_6k.htm | 0001640334-26-000562 |
| Document: 0001640334-26-000562-index-headers.html | 0001640334-26-000562 |
| Document: 0001640334-26-000562-index.html | 0001640334-26-000562 |
| Document: 0001640334-26-000562.txt | 0001640334-26-000562 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 6w ago | 20-F | $0.000200 $0.000200 | · 0.00% | ▼ −0.46% | $0.0410 (−20400.00%) |
Aug 31, 2026 8w ago | 6-K | $0.000200 $0.000200 | · 0.00% | ▲ +0.69% | $0.0410 (+20400.00%) |
Aug 7, 2026 11w ago | 6-K | $0.000200 $0.000200 | · 0.00% | ▲ +0.03% | $0.0410 (+20400.00%) |
Jun 3, 2026 20w ago | 6-K | $0.1269 $0.0646 | ▲ +49.09% | ▲ +49.50% | $0.0410 (+67.69%) |
Mar 27, 2026 30w ago | 6-K | $0.0705 $0.0700 | ▼ −0.71% | ▼ −3.60% | $0.0410 (−41.84%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers